Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Accounts Payables (2023 - 2025)

Contineum Therapeutics has reported Accounts Payables over the past 3 years, most recently at $786000.0 for Q3 2025.

  • Quarterly results put Accounts Payables at $786000.0 for Q3 2025, down 43.74% from a year ago — trailing twelve months through Sep 2025 was $786000.0 (down 43.74% YoY), and the annual figure for FY2024 was $1.8 million, up 185.2%.
  • Accounts Payables for Q3 2025 was $786000.0 at Contineum Therapeutics, down from $2.0 million in the prior quarter.
  • Over the last five years, Accounts Payables for CTNM hit a ceiling of $3.6 million in Q1 2025 and a floor of $570000.0 in Q1 2024.
  • Median Accounts Payables over the past 3 years was $1.1 million (2024), compared with a mean of $1.4 million.
  • Peak annual rise in Accounts Payables hit 539.47% in 2025, while the deepest fall reached 43.74% in 2025.
  • Contineum Therapeutics' Accounts Payables stood at $635000.0 in 2023, then surged by 185.2% to $1.8 million in 2024, then tumbled by 56.6% to $786000.0 in 2025.
  • The last three reported values for Accounts Payables were $786000.0 (Q3 2025), $2.0 million (Q2 2025), and $3.6 million (Q1 2025) per Business Quant data.